9:42 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The Swiss pharmaceutical company announced a deal to buy Carmot Therapeutics for $2.7 billion with up to $400 million in additional payments based on drug-development milestones. Roche said it would be gaining Carmot's research-and-development portfolio, including drugs it's developing to treat obesity and type-1 and type-2 diabetes. Dow Jones & Co. owns Factiva. (susan.solan@wsj.com)

(END) Dow Jones Newswires

December 04, 2023 09:57 ET (14:57 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 2 2025 まで 3 2025 Roche (QX)のチャートをもっと見るにはこちらをクリック
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 3 2024 まで 3 2025 Roche (QX)のチャートをもっと見るにはこちらをクリック